Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene; Celgene
Thomas J. Ervin
No relevant relationships to disclose
Francis P. Arena
Research Funding - Clinical Research Alliance
E. Gabriela Chiorean
Research Funding - Celgene
Jeffrey R. Infante
No relevant relationships to disclose
Malcolm J. Moore
Consultant or Advisory Role - Celgene; Celgene (U)
Research Funding - Celgene; Celgene
Thomas E. Seay
Research Funding - Celgene
Sergei Tjulandin
No relevant relationships to disclose
Wen Wee Ma
Research Funding - Celgene
Mansoor N. Saleh
Research Funding - Celgene
Marion Harris
No relevant relationships to disclose
Michele Reni
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Ramesh K. Ramanathan
Consultant or Advisory Role - Celgene (U)
Honoraria - Abraxis BioScience
Research Funding - Celgene
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Manuel Hidalgo
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Eric Van Cutsem
Research Funding - Celgene
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Xinyu Wei
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jose Luis Iglesias
Employment or Leadership Position - Bionomics
Stock Ownership - Celgene
Markus Frederic Renschler
Employment or Leadership Position - Celgene
Stock Ownership - Celgene